Acuta Capital Partners LLC Invests $274,000 in Benitec Biopharma Inc. (NASDAQ:BNTC)

Acuta Capital Partners LLC acquired a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 29,800 shares of the biotechnology company’s stock, valued at approximately $274,000. Acuta Capital Partners LLC owned 0.28% of Benitec Biopharma as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in Benitec Biopharma by 53.0% in the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,884 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma during the 2nd quarter worth approximately $358,000. Janus Henderson Group PLC boosted its holdings in Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 64,092 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in Benitec Biopharma in the second quarter valued at approximately $5,881,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BNTC. Oppenheimer assumed coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 target price on the stock. JMP Securities raised their target price on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research note on Monday, October 14th. Guggenheim initiated coverage on Benitec Biopharma in a research note on Thursday, September 12th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $22.60.

Benitec Biopharma Price Performance

Shares of Benitec Biopharma stock opened at $9.73 on Thursday. The business has a 50-day moving average price of $10.14 and a 200 day moving average price of $9.12. Benitec Biopharma Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $12.89.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.